Scholar Rock Holding 将来の成長

Future 基準チェック /26

Scholar Rock Holding利益と収益がそれぞれ年間53.4%と68.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-23.1% 56.9%なると予測されています。

主要情報

53.4%

収益成長率

56.9%

EPS成長率

Biotechs 収益成長	42.4%
収益成長率	68.4%
将来の株主資本利益率	-23.1%
アナリストカバレッジ	Good
最終更新日	26 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:2QK - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	184	-114	-125	-74	8
12/31/2025	26	-244	-206	-229	9
12/31/2024	N/A	-243	-155	-200	9
9/30/2024	N/A	-226	-189	-189	N/A
6/30/2024	N/A	-204	-169	-169	N/A
3/31/2024	N/A	-183	-152	-152	N/A
12/31/2023	N/A	-166	-145	-145	N/A
9/30/2023	N/A	-159	-137	-137	N/A
6/30/2023	N/A	-160	-131	-131	N/A
3/31/2023	N/A	-166	-134	-133	N/A
12/31/2022	33	-135	-134	-133	N/A
9/30/2022	37	-131	-138	-136	N/A
6/30/2022	43	-125	-149	-146	N/A
3/31/2022	47	-112	-146	-143	N/A
12/31/2021	19	-132	-132	-127	N/A
9/30/2021	18	-122	-121	-114	N/A
6/30/2021	16	-109	-109	-101	N/A
3/31/2021	15	-97	-96	-89	N/A
12/31/2020	15	-86	-64	-60	N/A
9/30/2020	20	-71	-60	-57	N/A
6/30/2020	21	-64	-50	-48	N/A
3/31/2020	22	-57	-48	-45	N/A
12/31/2019	20	-51	-66	-63	N/A
9/30/2019	13	-54	6	8	N/A
6/30/2019	8	-49	12	14	N/A
3/31/2019	3	-51	17	19	N/A
12/31/2018	N/A	-49	23	25	N/A
9/30/2018	N/A	-43	-37	-37	N/A
6/30/2018	N/A	-38	N/A	-33	N/A
3/31/2018	N/A	-29	N/A	-27	N/A
12/31/2017	N/A	-25	N/A	-22	N/A
12/31/2016	0	-16	N/A	-15	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 2QK今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 2QK今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 2QK今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 2QKの収益 ( 68.4% ) German市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 2QKの収益 ( 68.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 2QK 3 年以内に赤字になると予測されています。

Scholar Rock Holding 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Recent updates

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $300.00002 million.

Scholar Rock Holding Corporation has filed a Follow-on Equity Offering in the amount of $275 million.

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 Sapphire Study in Patients with Spinal Muscular Atrophy

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

New major risk - Financial position

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

New major risk - Financial position

President recently sold €170k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Senior VP & Head of Research recently sold €268k worth of stock

New major risk - Revenue and earnings growth

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Full year 2022 earnings released: US$2.26 loss per share (vs US$3.59 loss in FY 2021)

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock Announces Chief Executive Officer Changes

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Scholar Rock Holding Corporation Provides Pipeline Updates

First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.76 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Forecast to breakeven in 2025

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Full year 2020 earnings released: US$2.81 loss per share (vs US$1.85 loss in FY 2019)

Revenue misses expectations

New 90-day high: €50.00

Scholar Rock Announces Executive Promotions

New 90-day high: €47.40

New 90-day high: €43.80

Third quarter 2020 earnings released: US$0.79 loss per share

Revenue misses expectations

New 90-day high: €31.80

Earnings released

Scholar Rock Holding Corporation to Report Q2, 2020 Results on Aug 07, 2020

Scholar Rock Holding Corporation Announces Executive Changes, Effective August 1, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘